-
The threat of a post-antibiotic era when once treatable infections are impervious to all available drugs is typically evoked as some future specter to force present change. In reality, at the very narrow margins, it is already here.
-
In an attempt to preserve antibiotic efficacy and stem the rise of drug-resistant bacteria, there is an urgent call for antibiotic stewardship programs (ASP) across the health care continuum.
-
Calling for the development of a game-changing universal flu vaccine, the authors of a sweeping new flu report warn that the American public may ultimately lose faith in national flu recommendations that overstate the benefit of current immunization.
-
A randomized vehicle-controlled phase 3 trial of topical PM 15% vs. PM 15% + GM 0.5% vs. vehicle control was conducted in Tunisian patients with CL due to Leishmania major. 375 patients were randomized. Patients had from 1-5 lesions each. Lesions were treated daily for 20 days.
-
In this issue: Calcium supplementation in women; type 2 diabetes treatments and pancreatitis risk; treating chronic idiopathic urticaria; rivaroxaban and VTE; and FDA actions.
-
Seasonal influenza is a major worldwide threat to human health. Vaccination against influenza is an important intervention to prevent disease especially in vulnerable populations, such as the elderly and immunocompromised individuals.
-
A tripla ® is a branded, combination once-daily tablet recommended as first-line anti-retroviral therapy (ART) for HIV in the United States (containing tenofovir-emtricitabine-efavirenz).
-
Patients with cancer in general, but particularly those with hematologic malignancies, are at increased risk for infectious diseases, some of which are preventable by vaccination.
-
In the January 2013 issue of Infectious Disease Alert the initial reports of a novel coronavirus were reviewed.1 These included 5 cases (including 3 deaths) from Saudi Arabia, two cases from Qatar and two cases (both fatal) from Jordan.
-
Lu et al prospectively studied 165 patients with culture-confirmed (bronchoalveolar lavage samples), ventilator-associated pneumonia (VAP) caused by either Pseudomonas aeruginosa or Acinetobacter baumannii. Antibiotic therapy was based on antibiotic sensitivity.